Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials

Documenti analoghi

• Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
  di: Domenica M. Rubino, et al.
  Pubblicazione: (2025)
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
  di: Michelle Look, et al.
  Pubblicazione: (2025)
• Early‐Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials
  di: Evgenia Gourgari, et al.
  Pubblicazione: (2025)
• Tirzepatide Associated With Improved Health‐Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT ‐4
  di: Theresa Hunter Gibble, et al.
  Pubblicazione: (2025)
• Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program
  di: Beverly G. Tchang, et al.
  Pubblicazione: (2025)